Free Trial

Vaxcyte (PCVX) Competitors

$70.97
-1.54 (-2.12%)
(As of 06/7/2024 ET)

PCVX vs. FMTX, SRRK, EDIT, ADVM, SGMO, BNTX, ARGX, NBIX, TECH, and QGEN

Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Forma Therapeutics (FMTX), Scholar Rock (SRRK), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), BioNTech (BNTX), argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), and Qiagen (QGEN). These companies are all part of the "biological products, except diagnostic" industry.

Vaxcyte vs.

Forma Therapeutics (NASDAQ:FMTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Forma Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Forma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forma Therapeutics$100.56M9.52-$172.96M-$4.00-5.00
VaxcyteN/AN/A-$402.27M-$4.28-16.73

Vaxcyte has a consensus target price of $78.50, suggesting a potential upside of 9.77%. Given Forma Therapeutics' higher probable upside, analysts clearly believe Vaxcyte is more favorable than Forma Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forma Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

87.4% of Forma Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 5.8% of Forma Therapeutics shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Forma Therapeutics has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

In the previous week, Vaxcyte had 12 more articles in the media than Forma Therapeutics. MarketBeat recorded 12 mentions for Vaxcyte and 0 mentions for Forma Therapeutics. Forma Therapeutics' average media sentiment score of 0.29 beat Vaxcyte's score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Overall Sentiment
Forma Therapeutics Neutral
Vaxcyte Neutral

Vaxcyte received 3 more outperform votes than Forma Therapeutics when rated by MarketBeat users. Likewise, 68.75% of users gave Vaxcyte an outperform vote while only 51.72% of users gave Forma Therapeutics an outperform vote.

CompanyUnderperformOutperform
Forma TherapeuticsOutperform Votes
30
51.72%
Underperform Votes
28
48.28%
VaxcyteOutperform Votes
33
68.75%
Underperform Votes
15
31.25%

Forma Therapeutics' return on equity of -28.83% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Forma TherapeuticsN/A -39.68% -35.33%
Vaxcyte N/A -28.83%-26.89%

Summary

Vaxcyte beats Forma Therapeutics on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCVX vs. The Competition

MetricVaxcyteBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$7.79B$2.94B$5.18B$8.19B
Dividend YieldN/A2.26%2.80%4.04%
P/E Ratio-16.7314.08136.6015.48
Price / SalesN/A299.592,517.6775.52
Price / CashN/A167.6034.4830.78
Price / Book5.494.424.954.35
Net Income-$402.27M-$46.10M$109.77M$215.65M
7 Day Performance1.88%0.39%-0.39%-0.86%
1 Month Performance6.03%-2.05%-0.16%-0.18%
1 Year Performance39.69%-3.51%-1.16%2.09%

Vaxcyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FMTX
Forma Therapeutics
0 of 5 stars
$20.01
flat
N/A+0.0%$957.54M$100.56M-5.00166
SRRK
Scholar Rock
4.5367 of 5 stars
$9.60
-2.3%
$25.17
+162.2%
+45.1%$765.60M$33.19M-4.59150Analyst Forecast
EDIT
Editas Medicine
3.6672 of 5 stars
$5.50
-1.8%
$13.27
+141.3%
-47.0%$452.32M$78.12M-2.62265Gap Down
ADVM
Adverum Biotechnologies
3.6127 of 5 stars
$7.55
-0.4%
$29.00
+284.1%
-46.8%$156.74M$3.60M-0.74121Positive News
SGMO
Sangamo Therapeutics
0.6786 of 5 stars
$0.58
-1.6%
$5.67
+884.0%
-53.0%$119.51M$176.23M-0.31405Positive News
BNTX
BioNTech
1.5131 of 5 stars
$102.47
0.0%
$111.70
+9.0%
-7.3%$24.36B$4.13B204.946,133Positive News
ARGX
argenx
3.3694 of 5 stars
$384.90
0.0%
$520.68
+35.3%
-3.4%$22.87B$1.27B-68.001,148Positive News
NBIX
Neurocrine Biosciences
4.7033 of 5 stars
$133.71
+0.0%
$150.85
+12.8%
+39.5%$13.46B$1.89B36.831,400Positive News
TECH
Bio-Techne
3.9899 of 5 stars
$79.77
+0.6%
$81.00
+1.5%
-4.6%$12.57B$1.14B63.313,050Positive News
QGEN
Qiagen
4.0673 of 5 stars
$44.74
+0.2%
$50.95
+13.9%
-4.9%$10.21B$1.97B30.005,967

Related Companies and Tools

This page (NASDAQ:PCVX) was last updated on 6/7/2024 by MarketBeat.com Staff

From Our Partners